Moreover, the synergistic combination of the CARM1 inhibitor EZM2302 and an anti-PD-1 antibody significantly inhibited the growth of circHMGB2-overexpressing tumors in mice with a humanized immune system and in immunocompetent mice; these results indicated a promising strategy for immunotherapy for the subgroup of NSCLC patients with high circHMGB2 expression. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.